# SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

> **NCT02924714** · NA · SUSPENDED · sponsor: **Oslo University Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **OTHER:** Discontinuation of imatinib

## Key facts

- **NCT ID:** NCT02924714
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-01
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 31 (ESTIMATED)
- **Why stopped:** Slow accrual
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924714, "SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02924714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*